BACKGROUND The American Heart Association updated its recommendations for antibiotic prophylaxis (AP) to pre-
I nfective endocarditis (IE) is a life-
threatening infection with high morbidity and w30% first-year mortality (1) .
Although uncommon, a large number of individuals with predisposing cardiac conditions are at increased risk of IE (2) .P r e v e n ting IE in those at risk has been the focus of international guidelines since the American Heart Association (AHA) first advocated antibiotic prophylaxis (AP) before invasive medical and dental procedures in 1955 (3).
However, there has never been a trial of AP to define its efficacy (4) .T h i s ,a n dc o n c e r n s 
METHODS
The MarketScan databases are a collection of HIPAA (Health Insurance Portability and Accountability Act)-compliant datasets that integrate deidentified patient-level health data across commercial health insurance, Medicare supplemental insurance, and Medicaid programs covering physician office visits, inpatient and outpatient hospital services, and outpatient prescription drug coverage (19, 20) .T h e y p r o v i d eo n eo ft h el a r g e s tU . S .h e a l t hc a r ed a t a samples with 240 million covered lives and 32 billion service records (19, 20) A l lc o m m e r c i a li n s u r a n c e ,M e d i c a r e ,a n dM e d i c a i d enrollees over the age of 18 years, with linked prescription benefit data, were identified for the period Association guideline on prevention of infective endocarditis; and has served as a consultant for Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. (24) . Previous studies, however, have shown that it can take 18 months following guideline change for new AP recommendations to be widely adopted (8, 21) .F o rd e s c r i p t i v e purposes, the data were therefore divided into In total, there were 20,340 episodes of IE and 1,910,544 AP prescriptions issued. The breakdown of this by risk and health insurer type is show in Table 1 . À0.12 to 0.20).
COST OF INPATIENT IE CARE AND AP PRESCRIPTIONS.
The reimbursed costs for inpatient IE care/10,000 enrollees rose throughout the period of study ( Figure 4A 
This was because the cost of treating IE cases Table 4 , Online Figure 7 ).
DISCUSSION
This study provides an estimate of the proportions of the U.S. population at moderate (7.21%) or high risk Table 1) .
There was a decline in IE incidence in all 3 risk 
CONCLUSIONS
Although our data do not establish a cause-effect relationship between reduction in AP use and increase in IE incidence, they do provide support for the current AHA and ESC recommendations that focus AP on those at high risk of IE. Given the importance that these recommendations place on AP use in this patient subgroup, the fall in AP prescribing in those at high risk is of concern and warrants investigation.
T h eb o r d e r l i n es i g n i ficant IE increase in those at moderate risk of IE, despite a large fall in AP prescribing, is concordant with current guidance that suggests that AP is unlikely to be of benefiti nt h i s group as a whole; however, further investigation into specific heart valve conditions within the moderaterisk group may be warranted. 
